Adherium Announces Patient Program with Connecticut Children’s Medical Center to Explore Best Practices for Access to Better Asthma Care Nationally

/in

10 Jul 2018 San Mateo, CA – July 10, 2018: Adherium (ASX: ADR), a leading digital health company that improves medication adherence and patient outcomes, today announced a patient program with Connecticut Children’s Medical Center to help patients with asthma manage their condition with Adherium’s technology, the Hailie™ solution. Connecticut Children’s Medical Center’s close work with the […]

Read more

Adherium’s Technology Used for Large Scale Electronic Data Capture in Landmark Mild-Asthma Trials

/in

18 May 2018 San Mateo, CA – May 18, 2018: Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, announced the extensive use of it’s Hailie™(previously known as Smartinhaler™) technology in two landmark clinical trials investigating the treatment of mild asthma, which have just been published in the New England Journal […]

Read more

Adherium Launches the Hailie™ Global Brand to Connect People with Asthma and COPD to Better Care

/in

17 May 2018 San Mateo, CA – May 16th, 2018: Adherium (ASX: ADR), an award-winning digital health company that improves medication adherence, patient outcomes and engagement, today announced the launch of the Hailie™ global brand to connect people with asthma and COPD to better care. The launch is a rebrand of the existing Smartinhaler™ brand, and […]

Read more

New medical device platform takes flight: Global Health Sciences Fund invests in Canary Medical’s proprietary, “smart” implant technology designed to improve outcomes in post-surgical patients

/in

The Canary Health Implantable Reporting Processor (CHIRP) uses innovative sensor and novel communication technology in medical devices to enable remote patient monitoring. “Smart” medical devices will self-report on everything from patient activity to recovery and even treatment failure, without the need for physician intervention or a dependence upon patient compliance. May 17, 2018 13:06 ET […]

Read more

Adherium to Present at the Chardan Digital Health Conference

/in

15 May 2018 San Mateo, CA – May 1, 2018: Adherium, an award-winning digital health company that improves medication adherence and patient outcomes, today announced the Company will be participating in the upcoming Chardan Digital Health Conference in San Francisco, CA on Tuesday, May 22, 2018. Arik Anderson, CEO, is scheduled to provide a business overview […]

Read more

Adherium Announces Program with Vitalus Health on World Asthma Day

/in

01 May 2018 San Mateo, CA – May 1, 2018: In conjunction with World Asthma Day, Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, announced today it has agreed to launch a program with Vitalus Health, targeting patients with chronic obstructive pulmonary disease (COPD) using the Adherium Smartinhaler technology.  Vitalus […]

Read more

Adherium Receives U.S. 510(k) Clearance for Over-the-Counter Sales of its Smartinhaler™ Sensor

/in

San Mateo, CA – March 27, 2018: Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, today announced the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for over-the-counter (OTC) sales of its SmartinhalerTM sensor for AstraZeneca’s Symbicort® aerosol asthma inhaler. The Smartinhaler sensor is a device installed onto a […]

Read more

AmpliPhi Biosciences Announces Registered Direct Offering of Common Stock

/in

CATEGORY: Featured Tuesday, March 20, 2018 8:00 am EDT SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has entered into definitive purchase agreements with certain institutional investors to sell in a registered […]

Read more

AVITA Medical Announces Government Funded Clinical Trial of RECELL® in China

/in

Also Announces that Major Hospital Will Host New Training Center for RECELL in Beijing Valencia, CA, USA, and Melbourne, Australia, 19 March 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced the commencement of a randomized, controlled clinical trial of RECELL® in the treatment of deep partial-thickness (second-degree) burns in China. RECELL is a medical […]

Read more

AmpliPhi to Collaborate with Western Sydney Local Health District and Westmead Institute for Medical Research on Expanded Access for Investigational Bacteriophage Therapeutics AB-SA01 and AB-PA01

/in

CATEGORY: Featured Monday, March 19, 2018 4:10 pm EDT SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB “The promising clinical results I have observed to-date support the potential of bacteriophage therapeutics to be a safe and potent adjunct treatment for serious bacterial infections.” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company […]

Read more